Vera Therapeutics Q1 net loss widens

Vera Therapeutics

07/05/2026 12:44

Overview

U.S. biotech firm's Q1 net loss widened

Operating expenses more than doubled yr/yr as company prepares for potential drug launch

Result Drivers

PRE-COMMERCIAL SPENDING - Operating expenses rose sharply due to investments in sales, marketing, market access, compliance, and commercial operations ahead of potential atacicept launch

Company press release: ID:nGNX2fp8Qp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Miss
-$121.03 mln
-$89.89 mln (8 Analysts)
Q1 Operating Income
Miss
-$125.13 mln
-$92.74 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vera Therapeutics, Inc is $78.00, about 113.1% above its May 6 closing price of $36.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)